Experiment 67542
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | IV |
| Organism | Ginkgo biloba (GINKGOACEAE) |
| Citation | HAUNS,B: HARING,B: KOHLER,S: MROSS,K: UNGER,C:. (2001). PHASE II STUDY OF COMBINED 5-FLUOROURACIL/GINKGO BILOBA EXTRACT (GBE 761 ONC) THERAPY IN 5-FLUOROURACIL PRETREATED PATIENTS WITH ADVANCED COLORECTAL CANCER.. 15(1) |
| Amount utilized | |
| Compound isolated | |
| Disease | THE AIM OF THE STUDY WAS TO EVALUATE THE EFFICACY, TOLERABILITY AND QUALITY OF LIFE IN 5-FLUOROURACIL (5-FU) PRETREATED COLORECTAL CANCER PATIENTS AFTER COMBINED 5-FU AND GINKGO BILOBA EXTRACT GBE 761 ONC THERAPY. FOLLOWING CONVENTIONAL 5-FU THERAPY, 44 PATIENTS WITH ADVANCED PROGRESSIVE COLORECTAL CANCER WERE TREATED EVERY 3 WEEKS WITH COURSES OF 350MG GBE 761 ONC AS A 30 MIN I.V. INFUSION ON DAYS 1-6 FOLLOWED BY 500 MG/M-2/D 5-FU AS A 30MIN I.V. INFUSION ON DAYS 2-6. THE RESPONSE TO THERAPY WAS EVALUATED AFTER THE SECOND AND FOURTH COURSE OF TREATMENT. OUR RESULTS SUGGEST A GOOD BENEFIT-RISK RATIO OF THE COMBINED 5-FU AND GBE 761 ONC THERAPY AS SECOND LINE TREATMENT IN METASTATIC COLORECTAL CANCER. THE SURVIVAL TIME WAS SIMILAR TO THAT KNOWN FROM SECOND LINE TREATMENT ACCORDING TO THE ARDALAN SCHEME. A COMMERCIAL PRODUCT, EGB-761, WAS USED. |
| Dose amount | 350.0 MG |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | DAY |
| Dose expression | DOSE |
| Extract | ACETONE EXT |
| Gender | GIVEN TO BOTH SEXES |